XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism Oct 26, 2015 8:30am EDT
XOMA Announces Development and Commercialization Agreement for First-in-Class Anti-TGF-beta Antibody Program in Immuno-Oncology Oct 01, 2015 7:30am EDT
XOMA to Announce Second Quarter 2015 Financial Results and Host Webcast on August 6 Jul 16, 2015 4:35pm EDT
XOMA Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital Hyperinsulinism (HI) Jun 16, 2015 9:00am EDT
XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event May 28, 2015 8:30am EDT
